Business Context and Reporting Period
This Form 8-K is a current report filed by Catalyst Biosciences, Inc. (not Gyre Therapeutics, Inc.) on December 14, 2017, regarding events occurring on December 12, 2017. The filing addresses changes to the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Board Expansion: The Board of Directors increased the authorized number of directors to nine.
- New Appointment: Edward Williams was appointed as a Class I director, effective January 1, 2018, to fill a vacancy. His term expires at the 2019 annual stockholders' meeting.
- Resignation: Dr. Harold E. Selick resigned from the Board, effective February 15, 2018. The resignation is not due to any disagreement with the Company.
- Leadership Change: Augustine (Gus) Lawlor was appointed Chairman of the Board, effective February 15, 2018.
Compensation and Outlook
Compensatory Arrangements for Edward Williams:
- Initial Grant: Non-qualified stock option to purchase 10,000 shares, vesting monthly over three years.
- Annual Grant: Non-qualified stock option to purchase 5,000 shares at each annual meeting, vesting over one year.
- Cash Retainer: $35,000 annually, payable quarterly. This may be elected to be received in fully vested shares of common stock.
Outlook and Risks: The filing does not contain management commentary on business outlook, risks, contingencies, or unusual items beyond the personnel changes described.
Investor Verification Checklist
- Verify the exact effective dates for Edward Williams' appointment (Jan 1, 2018) and Dr. Selick's resignation (Feb 15, 2018).
- Confirm the vesting schedule details for the 10,000-share initial option grant to Mr. Williams.
- Review the Company's director compensation policy to understand the election process for the cash retainer versus stock.
- Check subsequent filings for the appointment of Mr. Williams to any board committees, as none were assigned at the time of this filing.